Meloxicam, a selective cyclooxygenase 2 (COX2) inhibitor, is a new type of nonsteroidal anti-inflammatory drug (NSAID) with low side effects and a long half-life for the treatment of rheumatoid arthritis and osteoarthritis [1–3]. The gene discussed is PTGS2; the disease is rheumatoid arthritis.